Monte Rosa gets $50 million milestone as Novartis starts Phase 2
Monte Rosa said it received a $50 million milestone payment after Novartis started a Phase 2 study of MRT-6160, also known as DDY391, in Sjögren’s disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
GLUE: Monte Rosa starts Phase 2 study of MRT-6160
GLUE-linked disclosure says Monte Rosa Therapeutics has initiated a Phase 2 clinical study for its VAV1-directed molecular glue degrader MRT-6160 (DDY391).